Gilead Sciences (GILD) 102.17 $GILD
No Easy Cure for What Ails Biotech Stocks
at The Street - 1 hr 41 mins ago
Meanwhile, make incremental moves until the onslaught in the space is over.
BIIB: 278.15 (+1.81), VRX: 100.62 (-17.99), GILD: 102.17 (+0.44), MYL: 38.92 (-1.97), AMGN: 151.90 (+1.81)
Polycythemia Vera Pipeline Review, H2 2015 - 10 Companies & 12 Drug Profiles
M2 - Thu Oct 22, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wswf9z/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Galena Biopharma, Inc. - Gilead Sciences, Inc. - Incyte Corporation - Italfarmaco S.p.A. - Karus Therapeutics Limited - miRagen Therapeutics, Inc. - Novartis AG - Onconova Therapeutics, Inc. - PharmaEssentia Corporation Drug Profiles - anagrelide hydrochloride CR - dasatinib - erismodegib - givinostat - idelalisib - KA-1463 - M-012 - MGN-4893 - momelotinib dihydrochloride - rigosertib sodium - ropeginterferon ALFA-2B - ruxolitinib phosphate For more information visit http://www.researchandmarkets.com/research/ws...hemia_vera
GILD: 102.17 (+0.44), INCY: 108.19 (+1.04), ONTX: 1.46 (unch), GALE: 1.63 (-0.02), BMY: 62.89 (+0.38), NVS: 92.22 (+0.63)
Gilead Announces Phase 3 Results for Genvoya(R) (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV
Business Wire - Thu Oct 22, 6:33AM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today announced 96-week results from two Phase 3 studies (Studies 104 and 111) evaluating its investigational once-daily single tablet regimen (STR), Genvoya(R) (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg or E/C/F/TAF), for the treatment of HIV-1 infection in treatment-naive adults. Genvoya was found to be statistically non-inferior to Stribild(R) (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg or E/C/F/TDF), based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL. Patients receiving Genvoya also had improved renal and bone laboratory parameters compared to those treated with Stribild. The data were presented at the 15th European AIDS Conference (EACS) in Barcelona (session: BD 01).
GILD: 102.17 (+0.44)
Battle Royale: Gilead Sciences Inc vs Celgene Corporation
Brian Feroldi, The Motley Fool - Motley Fool - Wed Oct 21, 2:09PM CDT
Photo by Mattza / Flickr creative Commons It's been a rough couple of months to be a biotech focused investor. Since peaking in price over the summer, biotech stocks on the whole have basically been in free-fall. The iShares Nasdaq Biotechnology...
GILD: 102.17 (+0.44), CELG: 116.39 (+0.47)
Stocks Turn Lower as Valeant Dents Biotech Sector
at The Street - Wed Oct 21, 9:41AM CDT
Stocks turn lower by mid-morning Wednesday as plummeting Valeant Pharmaceuticals shares pull the biotech sector to the downside.
BIIB: 278.15 (+1.81), TSLA: 214.09 (+4.00), VRX: 100.62 (-17.99), KMB: 120.98 (+2.89), IBB: 304.31 (-0.15), SBUX: 61.39 (+0.86), YHOO: 31.79 (+0.67), CMG: 658.43 (-7.24), ABBV: 53.38 (-0.45), GOOGL: 682.16 (+10.36), AAPL: 114.99 (+1.23), KO: 43.74 (+1.55), AMZN: 564.65 (+8.88), MU: 16.76 (+0.33), PFE: 33.05 (-0.41), FCAU: 15.31 (+0.11), BA: 146.82 (+5.63), WDC: 71.46 (+0.02), CELG: 116.39 (+0.47), GILD: 102.17 (+0.44), LRCX: 72.63 (+1.84), GM: 35.47 (+0.05), MCD: 110.33 (+7.79), KLAC: 65.08 (+1.10), RACE: 56.48 (+1.48), SNDK: 76.89 (+0.11)
Stock Market News for October 21, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:10AM CDT
Benchmarks ended in the red on Tuesday, dragged down by declines in biotech and healthcare stocks
BIIB: 278.15 (+1.81), HOG: 47.61 (+0.58), IBM: 144.48 (+3.56), GILD: 102.17 (+0.44), UTX: 99.92 (+1.95), PFE: 33.05 (-0.41), MRK: 50.80 (+0.21), AMGN: 151.90 (+1.81), VZ: 45.79 (+0.93), REGN: 521.28 (+2.75), TRV: 112.40 (+1.70), CELG: 116.39 (+0.47)
Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease
Business Wire - Wed Oct 21, 9:00AM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today confirmed that the company fulfilled a request for compassionate access to GS-5734, a novel nucleotide analogue in development for the potential treatment of Ebola Virus Disease (EVD). The request was received last week and drug was shipped later the same day. The compound is currently being provided to a female patient in the United Kingdom, as described earlier today by officials from the Royal Free Hospital in London.
GILD: 102.17 (+0.44)
These 10 S&P 500 Companies Are Spending Loads of Cash on Stock Buybacks
at The Street - Wed Oct 21, 7:10AM CDT
The companies of the S&P 500 spent $555.5 billion on stock buybacks in the period of a year -- and 10 firms spent nearly a quarter that amount combined.
JNJ: 98.79 (+1.16), GILD: 102.17 (+0.44), PFE: 33.05 (-0.41), QCOM: 60.54 (+1.57), XOM: 82.26 (+2.05), WFC: 54.31 (+1.19), INTC: 34.38 (+1.01), MSFT: 48.64 (+1.44), AAPL: 114.99 (+1.23), ORCL: 37.72 (+1.10)
Gilead Sciences to Release Third Quarter 2015 Financial Results on Tuesday, October 27, 2015
Business Wire - Tue Oct 20, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2015 financial results will be released on Tuesday, October 27, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the third quarter 2015 and provide a general business update.
GILD: 102.17 (+0.44)
Gilead, Merck Hepatitis C Rivalry Heats Up
at Investor's Business Daily - Tue Oct 20, 1:47PM CDT
Big biotech Gilead Sciences (GILD) got a price-target increase Tuesday as big pharma Merck (MRK) released new data on its hepatitis C regimen that could be a rival to Gilead's blockbuster franchise. Oppenheimer analyst Wendy Lam lifted her price...
GILD: 102.17 (+0.44), MRK: 50.80 (+0.21), ABBV: 53.38 (-0.45)
Stocks Slide as Health Care Selloff Dings Nasdaq
at The Street - Tue Oct 20, 1:37PM CDT
Stocks are lower by mid-afternoon Tuesday, pulled down by weakness in the tech and health care sectors.
BIIB: 278.15 (+1.81), TSLA: 214.09 (+4.00), GE: 29.69 (+0.84), VRX: 100.67 (-17.94), HOG: 47.61 (+0.58), UTX: 99.92 (+1.95), TFM: 26.06 (-0.58), IBB: 304.31 (-0.15), T: 34.10 (+0.50), SONC: 27.67 (-0.20), IBM: 144.48 (+3.56), S: 4.46 (+0.12), XLK: 42.67 (+0.97), SYF: 31.95 (-0.51), GOOGL: 682.16 (+10.36), TMUS: 40.51 (+0.29), YUM: 73.37 (-0.19), TRV: 112.40 (+1.70), AMSG: 60.52 (-11.04), AMZN: 564.40 (+8.63), PFE: 33.05 (-0.41), WDC: 71.46 (+0.02), VOD: 33.31 (+1.38), UAL: 55.77 (+1.22), NFLX: 97.80 (-0.16), LVLT: 48.40 (+1.04), GILD: 102.17 (+0.44), WTW: 14.95 (-0.45), TMH: 48.76 (-13.01), VZ: 45.79 (+0.93), SNDK: 76.89 (+0.11), BABA: 71.04 (+1.56)
Rotation Is Enough to Make Your Head Spin
at The Street - Tue Oct 20, 1:17PM CDT
Bad news isn't always a bad thing.
AMZN: 564.40 (+8.63), TSLA: 214.09 (+4.00), VRX: 100.60 (-18.01), HOG: 47.61 (+0.58), LMT: 216.67 (+5.11), ETN: 54.80 (+2.28), CLX: 123.37 (+1.31), UTX: 99.92 (+1.95), DAL: 50.76 (+1.32), CELG: 116.39 (+0.47), AGN: 255.04 (-3.96), GILD: 102.17 (+0.44), IBM: 144.48 (+3.56), GOOGL: 682.16 (+10.36), DOV: 64.46 (+2.58), PG: 75.22 (+1.63), PPG: 103.35 (+2.71), REGN: 521.28 (+2.75)
3 Big Questions for Gilead Sciences Inc. in Q3
Keith Speights, The Motley Fool - Motley Fool - Tue Oct 20, 9:12AM CDT
Image source: Gilead Sciences. Three months ago, there was plenty of anxiety among investors about how well Gilead Sciences performed during second quarter. Gilead's earnings announcement put all of those concerns to rest with stellar...
GILD: 102.17 (+0.44), ABBV: 53.38 (-0.45)
Johnson & Johnson Tells Gilead Sciences "Game On"
Todd Campbell, The Motley Fool - Motley Fool - Tue Oct 20, 6:02AM CDT
Source: Johnson & Johnson Johnson & Johnson's been elbow deep in cutting-edge hepatitis C research for years and those efforts have led to big treatment advances and top selling drugs, including Incivek and Olysio. However, J&J's...
JNJ: 98.79 (+1.16), GILD: 102.17 (+0.44), ACHN: 7.62 (-0.21)
Biotech Pullback: Look to Targeted Therapy Companies
ACCESSWIRE - Mon Oct 19, 8:28AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 19, 2015 / It's with good reason that there is a growing choir of voices heralding the science of targeted therapies as innovative approaches to improving medical care. Advancements in biology and technology underscore discovering specific receptors in cells that can be targeted for meaningful benefits in hard to treat diseases and conditions. There is also a significant diagnostic component in identifying which patients may benefit from certain therapies, while giving direction to avoid other treatments that likely would be ineffective. Combined, these streamline the treatment process and improve outcomes, equating to better quality of life for patients and a quantifiable savings to overburdened healthcare systems.
LOXO: 23.09 (-0.51), MDT: 73.46 (+0.04), FMI: 22.03 (-0.04), GILD: 102.17 (+0.44), LH: 111.03 (-5.01), ABIO: 5.01 (+0.14), SNY: 49.98 (+0.83), CLBS: 1.31 (+0.02)
Abingworth Appoints Dr Shelley Chu as Partner
PR Newswire - Mon Oct 19, 3:30AM CDT
Abingworth, the international investment group dedicated to life sciences, today announced that Shelley Chu, MD, PhD has joined Abingworth as a Partner. Shelley, who brings more than 20 years of experience in venture capital, business development and strategic leadership, will source and manage deals across a broad range of therapeutic areas and stages of development from start-ups to late-stage investments.
GILD: 102.17 (+0.44)
Gilead Sciences: Stagnation Directly Ahead?
George Budwell, The Motley Fool - Motley Fool - Sun Oct 18, 3:07PM CDT
Over the last five years, Gilead Sciences has been one of the fastest-growing biotechs in the world. From June 2014 to June 2015, for example, Gilead's total revenue blasted northward at a compound annual growth rate of 30.1%, according to data...
GILD: 102.17 (+0.44)
The 5 Best Bargains in the Stock Market
Brian Feroldi, Selena Maranjian, Sean Williams, Dan Caplinger, and Alex DUMORTIER, CFA, The Motley Fool - Motley Fool - Sun Oct 18, 12:04PM CDT
Image by Pictures of Money Flickr Creative Commons3 With the S&P 500 in negative territory since the start of the year, several high quality stocks have found their way into the discount bin and can now be purchased at bargain prices. With...
F: 15.60 (+0.19), GILD: 102.17 (+0.44), AMGN: 151.90 (+1.81), AAPL: 114.99 (+1.23)
Investing Moves for a No-Growth World; ETF Distortion: Jim Cramer's Best Blogs
at The Street - Fri Oct 16, 8:00PM CDT
Catch up on Jim Cramer's ideas from this past week as he discusses the shift to higher-risk investing, and the outsize power of ETFs and futures in the market now.
BIIB: 278.15 (+1.81), BMRN: 102.22 (-1.72), DAL: 50.76 (+1.32), C: 52.62 (+0.81), WMT: 58.90 (+0.26), KKR: 17.53 (+0.48), PANW: 163.55 (+3.74), ADBE: 88.40 (+2.27), V: 76.72 (+1.26), DG: 67.14 (-0.41), GOOGL: 682.16 (+10.36), CAT: 72.15 (+2.48), MA: 98.50 (+1.90), REGN: 521.28 (+2.75), AMZN: 564.40 (+8.63), KR: 38.31 (+0.23), SWKS: 80.76 (+3.09), FB: 98.49 (+1.38), NXPI: 95.63 (+4.31), BA: 146.82 (+5.63), CELG: 116.39 (+0.47), NFLX: 97.80 (-0.16), HCA: 65.14 (-6.06), AA: 9.24 (+0.13), GS: 183.69 (+3.99), QRVO: 49.65 (+1.15), GILD: 102.17 (+0.44), RHT: 77.80 (+0.99), WDAY: 80.39 (+2.16), FDC: 15.50 (+0.14), AVGO: 124.84 (+4.34), BABA: 71.04 (+1.56), CRM: 77.93 (+2.10)
No Easy Cure for What Ails Biotech Stocks
at The Street - 1 hr 41 mins ago
Meanwhile, make incremental moves until the onslaught in the space is over.
BIIB: 278.15 (+1.81), VRX: 100.62 (-17.99), GILD: 102.17 (+0.44), MYL: 38.92 (-1.97), AMGN: 151.90 (+1.81)
Polycythemia Vera Pipeline Review, H2 2015 - 10 Companies & 12 Drug Profiles
M2 - Thu Oct 22, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wswf9z/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Galena Biopharma, Inc. - Gilead Sciences, Inc. - Incyte Corporation - Italfarmaco S.p.A. - Karus Therapeutics Limited - miRagen Therapeutics, Inc. - Novartis AG - Onconova Therapeutics, Inc. - PharmaEssentia Corporation Drug Profiles - anagrelide hydrochloride CR - dasatinib - erismodegib - givinostat - idelalisib - KA-1463 - M-012 - MGN-4893 - momelotinib dihydrochloride - rigosertib sodium - ropeginterferon ALFA-2B - ruxolitinib phosphate For more information visit http://www.researchandmarkets.com/research/ws...hemia_vera
GILD: 102.17 (+0.44), INCY: 108.19 (+1.04), ONTX: 1.46 (unch), GALE: 1.63 (-0.02), BMY: 62.89 (+0.38), NVS: 92.22 (+0.63)
Gilead Announces Phase 3 Results for Genvoya(R) (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV
Business Wire - Thu Oct 22, 6:33AM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today announced 96-week results from two Phase 3 studies (Studies 104 and 111) evaluating its investigational once-daily single tablet regimen (STR), Genvoya(R) (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg or E/C/F/TAF), for the treatment of HIV-1 infection in treatment-naive adults. Genvoya was found to be statistically non-inferior to Stribild(R) (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg or E/C/F/TDF), based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL. Patients receiving Genvoya also had improved renal and bone laboratory parameters compared to those treated with Stribild. The data were presented at the 15th European AIDS Conference (EACS) in Barcelona (session: BD 01).
GILD: 102.17 (+0.44)
Battle Royale: Gilead Sciences Inc vs Celgene Corporation
Brian Feroldi, The Motley Fool - Motley Fool - Wed Oct 21, 2:09PM CDT
Photo by Mattza / Flickr creative Commons It's been a rough couple of months to be a biotech focused investor. Since peaking in price over the summer, biotech stocks on the whole have basically been in free-fall. The iShares Nasdaq Biotechnology...
GILD: 102.17 (+0.44), CELG: 116.39 (+0.47)
Stocks Turn Lower as Valeant Dents Biotech Sector
at The Street - Wed Oct 21, 9:41AM CDT
Stocks turn lower by mid-morning Wednesday as plummeting Valeant Pharmaceuticals shares pull the biotech sector to the downside.
BIIB: 278.15 (+1.81), TSLA: 214.09 (+4.00), VRX: 100.62 (-17.99), KMB: 120.98 (+2.89), IBB: 304.31 (-0.15), SBUX: 61.39 (+0.86), YHOO: 31.79 (+0.67), CMG: 658.43 (-7.24), ABBV: 53.38 (-0.45), GOOGL: 682.16 (+10.36), AAPL: 114.99 (+1.23), KO: 43.74 (+1.55), AMZN: 564.65 (+8.88), MU: 16.76 (+0.33), PFE: 33.05 (-0.41), FCAU: 15.31 (+0.11), BA: 146.82 (+5.63), WDC: 71.46 (+0.02), CELG: 116.39 (+0.47), GILD: 102.17 (+0.44), LRCX: 72.63 (+1.84), GM: 35.47 (+0.05), MCD: 110.33 (+7.79), KLAC: 65.08 (+1.10), RACE: 56.48 (+1.48), SNDK: 76.89 (+0.11)
Stock Market News for October 21, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:10AM CDT
Benchmarks ended in the red on Tuesday, dragged down by declines in biotech and healthcare stocks
BIIB: 278.15 (+1.81), HOG: 47.61 (+0.58), IBM: 144.48 (+3.56), GILD: 102.17 (+0.44), UTX: 99.92 (+1.95), PFE: 33.05 (-0.41), MRK: 50.80 (+0.21), AMGN: 151.90 (+1.81), VZ: 45.79 (+0.93), REGN: 521.28 (+2.75), TRV: 112.40 (+1.70), CELG: 116.39 (+0.47)
Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease
Business Wire - Wed Oct 21, 9:00AM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today confirmed that the company fulfilled a request for compassionate access to GS-5734, a novel nucleotide analogue in development for the potential treatment of Ebola Virus Disease (EVD). The request was received last week and drug was shipped later the same day. The compound is currently being provided to a female patient in the United Kingdom, as described earlier today by officials from the Royal Free Hospital in London.
GILD: 102.17 (+0.44)
These 10 S&P 500 Companies Are Spending Loads of Cash on Stock Buybacks
at The Street - Wed Oct 21, 7:10AM CDT
The companies of the S&P 500 spent $555.5 billion on stock buybacks in the period of a year -- and 10 firms spent nearly a quarter that amount combined.
JNJ: 98.79 (+1.16), GILD: 102.17 (+0.44), PFE: 33.05 (-0.41), QCOM: 60.54 (+1.57), XOM: 82.26 (+2.05), WFC: 54.31 (+1.19), INTC: 34.38 (+1.01), MSFT: 48.64 (+1.44), AAPL: 114.99 (+1.23), ORCL: 37.72 (+1.10)
Gilead Sciences to Release Third Quarter 2015 Financial Results on Tuesday, October 27, 2015
Business Wire - Tue Oct 20, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2015 financial results will be released on Tuesday, October 27, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the third quarter 2015 and provide a general business update.
GILD: 102.17 (+0.44)
Gilead, Merck Hepatitis C Rivalry Heats Up
at Investor's Business Daily - Tue Oct 20, 1:47PM CDT
Big biotech Gilead Sciences (GILD) got a price-target increase Tuesday as big pharma Merck (MRK) released new data on its hepatitis C regimen that could be a rival to Gilead's blockbuster franchise. Oppenheimer analyst Wendy Lam lifted her price...
GILD: 102.17 (+0.44), MRK: 50.80 (+0.21), ABBV: 53.38 (-0.45)
Stocks Slide as Health Care Selloff Dings Nasdaq
at The Street - Tue Oct 20, 1:37PM CDT
Stocks are lower by mid-afternoon Tuesday, pulled down by weakness in the tech and health care sectors.
BIIB: 278.15 (+1.81), TSLA: 214.09 (+4.00), GE: 29.69 (+0.84), VRX: 100.67 (-17.94), HOG: 47.61 (+0.58), UTX: 99.92 (+1.95), TFM: 26.06 (-0.58), IBB: 304.31 (-0.15), T: 34.10 (+0.50), SONC: 27.67 (-0.20), IBM: 144.48 (+3.56), S: 4.46 (+0.12), XLK: 42.67 (+0.97), SYF: 31.95 (-0.51), GOOGL: 682.16 (+10.36), TMUS: 40.51 (+0.29), YUM: 73.37 (-0.19), TRV: 112.40 (+1.70), AMSG: 60.52 (-11.04), AMZN: 564.40 (+8.63), PFE: 33.05 (-0.41), WDC: 71.46 (+0.02), VOD: 33.31 (+1.38), UAL: 55.77 (+1.22), NFLX: 97.80 (-0.16), LVLT: 48.40 (+1.04), GILD: 102.17 (+0.44), WTW: 14.95 (-0.45), TMH: 48.76 (-13.01), VZ: 45.79 (+0.93), SNDK: 76.89 (+0.11), BABA: 71.04 (+1.56)
Rotation Is Enough to Make Your Head Spin
at The Street - Tue Oct 20, 1:17PM CDT
Bad news isn't always a bad thing.
AMZN: 564.40 (+8.63), TSLA: 214.09 (+4.00), VRX: 100.60 (-18.01), HOG: 47.61 (+0.58), LMT: 216.67 (+5.11), ETN: 54.80 (+2.28), CLX: 123.37 (+1.31), UTX: 99.92 (+1.95), DAL: 50.76 (+1.32), CELG: 116.39 (+0.47), AGN: 255.04 (-3.96), GILD: 102.17 (+0.44), IBM: 144.48 (+3.56), GOOGL: 682.16 (+10.36), DOV: 64.46 (+2.58), PG: 75.22 (+1.63), PPG: 103.35 (+2.71), REGN: 521.28 (+2.75)
3 Big Questions for Gilead Sciences Inc. in Q3
Keith Speights, The Motley Fool - Motley Fool - Tue Oct 20, 9:12AM CDT
Image source: Gilead Sciences. Three months ago, there was plenty of anxiety among investors about how well Gilead Sciences performed during second quarter. Gilead's earnings announcement put all of those concerns to rest with stellar...
GILD: 102.17 (+0.44), ABBV: 53.38 (-0.45)
Johnson & Johnson Tells Gilead Sciences "Game On"
Todd Campbell, The Motley Fool - Motley Fool - Tue Oct 20, 6:02AM CDT
Source: Johnson & Johnson Johnson & Johnson's been elbow deep in cutting-edge hepatitis C research for years and those efforts have led to big treatment advances and top selling drugs, including Incivek and Olysio. However, J&J's...
JNJ: 98.79 (+1.16), GILD: 102.17 (+0.44), ACHN: 7.62 (-0.21)
Biotech Pullback: Look to Targeted Therapy Companies
ACCESSWIRE - Mon Oct 19, 8:28AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 19, 2015 / It's with good reason that there is a growing choir of voices heralding the science of targeted therapies as innovative approaches to improving medical care. Advancements in biology and technology underscore discovering specific receptors in cells that can be targeted for meaningful benefits in hard to treat diseases and conditions. There is also a significant diagnostic component in identifying which patients may benefit from certain therapies, while giving direction to avoid other treatments that likely would be ineffective. Combined, these streamline the treatment process and improve outcomes, equating to better quality of life for patients and a quantifiable savings to overburdened healthcare systems.
LOXO: 23.09 (-0.51), MDT: 73.46 (+0.04), FMI: 22.03 (-0.04), GILD: 102.17 (+0.44), LH: 111.03 (-5.01), ABIO: 5.01 (+0.14), SNY: 49.98 (+0.83), CLBS: 1.31 (+0.02)
Abingworth Appoints Dr Shelley Chu as Partner
PR Newswire - Mon Oct 19, 3:30AM CDT
Abingworth, the international investment group dedicated to life sciences, today announced that Shelley Chu, MD, PhD has joined Abingworth as a Partner. Shelley, who brings more than 20 years of experience in venture capital, business development and strategic leadership, will source and manage deals across a broad range of therapeutic areas and stages of development from start-ups to late-stage investments.
GILD: 102.17 (+0.44)
Gilead Sciences: Stagnation Directly Ahead?
George Budwell, The Motley Fool - Motley Fool - Sun Oct 18, 3:07PM CDT
Over the last five years, Gilead Sciences has been one of the fastest-growing biotechs in the world. From June 2014 to June 2015, for example, Gilead's total revenue blasted northward at a compound annual growth rate of 30.1%, according to data...
GILD: 102.17 (+0.44)
The 5 Best Bargains in the Stock Market
Brian Feroldi, Selena Maranjian, Sean Williams, Dan Caplinger, and Alex DUMORTIER, CFA, The Motley Fool - Motley Fool - Sun Oct 18, 12:04PM CDT
Image by Pictures of Money Flickr Creative Commons3 With the S&P 500 in negative territory since the start of the year, several high quality stocks have found their way into the discount bin and can now be purchased at bargain prices. With...
F: 15.60 (+0.19), GILD: 102.17 (+0.44), AMGN: 151.90 (+1.81), AAPL: 114.99 (+1.23)
Investing Moves for a No-Growth World; ETF Distortion: Jim Cramer's Best Blogs
at The Street - Fri Oct 16, 8:00PM CDT
Catch up on Jim Cramer's ideas from this past week as he discusses the shift to higher-risk investing, and the outsize power of ETFs and futures in the market now.
BIIB: 278.15 (+1.81), BMRN: 102.22 (-1.72), DAL: 50.76 (+1.32), C: 52.62 (+0.81), WMT: 58.90 (+0.26), KKR: 17.53 (+0.48), PANW: 163.55 (+3.74), ADBE: 88.40 (+2.27), V: 76.72 (+1.26), DG: 67.14 (-0.41), GOOGL: 682.16 (+10.36), CAT: 72.15 (+2.48), MA: 98.50 (+1.90), REGN: 521.28 (+2.75), AMZN: 564.40 (+8.63), KR: 38.31 (+0.23), SWKS: 80.76 (+3.09), FB: 98.49 (+1.38), NXPI: 95.63 (+4.31), BA: 146.82 (+5.63), CELG: 116.39 (+0.47), NFLX: 97.80 (-0.16), HCA: 65.14 (-6.06), AA: 9.24 (+0.13), GS: 183.69 (+3.99), QRVO: 49.65 (+1.15), GILD: 102.17 (+0.44), RHT: 77.80 (+0.99), WDAY: 80.39 (+2.16), FDC: 15.50 (+0.14), AVGO: 124.84 (+4.34), BABA: 71.04 (+1.56), CRM: 77.93 (+2.10)
